 | | Vol. 9.42 – 3 November, 2021 |
| |
|
|
| Investigators reported the discovery and characterization of PF-07321332, an orally bioavailable SARS-CoV-2 main protease inhibitor with in vitro pan-human coronavirus antiviral activity and excellent off-target selectivity and in vivo safety profiles.
[Science] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| The authors assessed the efficacy of fluvoxamine versus placebo in preventing hospitalisation defined as either retention in a COVID-19 emergency setting or transfer to a tertiary hospital due to COVID-19.
[Lancet Global Health] |
|
|
|
| Researchers monitored T cell responses to the Spike protein of SARS-CoV-2 in 71 healthy donors vaccinated with two doses of the Pfizer–BioNTech mRNA vaccine for up to six months after vaccination.
[Science Immunology] |
|
|
|
| Scientists used the high-density microarray patch to deliver a SARS-CoV-2 spike subunit vaccine directly to the skin.
[Science Advances] |
|
|
|
| Investigators examined potential confounders in COVID-19 respiratory microbiome studies by analyzing the upper and lower respiratory tract microbiome in well-phenotyped COVID-19 patients and controls combining microbiome sequencing, viral load determination, and immunoprofiling.
[Nature Communications] |
|
|
|
| Scientists expressed two neutralizing monoclonal antibodies against SARS-CoV-2; H4 and B38 in three formats: IgG1, IgA1 monomers, and IgA1 dimers in glycoengineered Nicotiana benthamiana plants.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Researchers found that, in contrast to current convention, “immunodominant” SARS-CoV-2 peptides defined by in silico methods often failed to elicit T cell responses recognizing naturally presented SARS-CoV-2 epitopes.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Cerebrospinal fluid (CSF) was assessed between day 1-30, between day 31-90, or later than 90 days of COVID-19 diagnosis.
[Annals of Neurology] |
|
|
|
| The authors assessed concentrations of chemerin, omentin, and vaspin among COVID-19 patients with an emphasis on adipokines relationship with COVID-19 severity, concomitant metabolic abnormalities and liver dysfunction.
[Scientific Reports] |
| | MORE IMMUNOLOGY OF INFECTIOUS DISEASE |
|
|
|
| Scientists examined the mechanisms that controlled bacterial infection in the peritoneum using a mouse model of abdominal sepsis following intraperitoneal Escherichia coli infection.
[Immunity] |
|
|
|
| Researchers investigated the human antibody repertoire, avidity maturation, epitope specificity, and function after immunization with a single dose of Vi-tetanus toxoid conjugate vaccine and after a booster with plain Vi polysaccharide.
[Science Immunology] |
|
|
|
| By studying the breadth of anti-hemagglutinin (HA) IgG, serum cytokines, and B and T cell responses by flow cytometry before and after influenza vaccination, investigators showed that formation of circulating T follicular helper cells was associated with high-titre antibody responses.
[eLife] |
|
|
|
| Researchers explored the roles of hepatocyte-derived exosomal microRNAs and B cell activating factor in the extrahepatic diseases of hepatitis C virus infection.
[mBio] |
|  |
|
|
|
| The authors highlight the current understanding, evolving concepts, and unanswered questions to determine the mechanisms by which viral infection can be exacerbated by, and even trigger, autoimmunity.
[Journal of Clinical Investigation] |
|
|
|
| Scientists focused on a family of S8 subtilisin-like serine proteases expressed as cell-envelope proteases by group A and group B streptococci.
[Journal of innate Immunity] |
|
|
|
|
| 7 Hills Pharma LLC announced that it has successfully completed its Phase I clinical trial to evaluate 7HP349, their lead molecule. 7HP349 is the first clinical candidate to emerge from 7HP’s proprietary and differentiated platform of allosteric integrin agonists.
[7 Hills Pharma LLC (GlobeNewswire, Inc.)] |
|
|
|
| Pfizer, Inc. and BioNTech SE announced that the FDA has authorized for emergency use the Pfizer-BioNTech COVID-19 Vaccine for children 5 through 11 years of age.
[Pfizer, Inc.] |
|
|
|
|
| November 10 – 19, 2021
Virtual |
|
|
|
|
|
| Stanford University – Stanford, California, United States |
|
|
|
| | Francis Crick Institute – London, United Kingdom |
|
|
|
| | Lund University – Malmö, Sweden |
|
|
|
| | Helmholtz Zentrum München – Augsburg, Germany |
|
|
|
| | University of Pittsburgh Graduate School of Public Health – Pittsburgh, Pennsylvania, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
